Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

Jose Rodriguez, Jorge Cortes, Terry Smith, Susan O'Brien, Mary Beth Rios, Moshe Talpaz, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic phase (ie, > 12 months after diagnosis). Trials conducted in this phase cannot be evaluated precisely unless the features that determine prognosis in late chronic-phase CML are identified. The purpose of this study is to define the prognostic determinants of late chronic-phase CML. Patients and Methods: From 1980 to 1997, 257 consecutive CML patients referred in late chronic phase were studied. Their clinical characteristics at the time of referral and their association with survival were investigated. A staging model was designed. Results: The median survival from time of referral was 43 months. Pretreatment characteristics associated with worse outcome included older age, poor performance status, splenomegaly; low albumin level, high percentage of blasts or basophils in peripheral blood (PB) or bone marrow, longer duration of chronic phase, and poor-risk group as defined by the Synthesis model. Prior exposure to IFN-A was not associated with worse outcome. By multivariate analysis, characteristics associated with shorter survival were age of 60 years or older, time from diagnosis of 3 years or greater, performance status of 1 or greater, PB basophils of 7% or greater, spleen 10 cm or greater, PB blasts 3% or greater, and albumin level less than 4 g/dL. A model that included age, duration of chronic phase, performance status, and PB basophils was generated. Patients with no, one, two, or three or greater adverse factors had median survivals of 71, 49, 26, and 19 months, respectively. Conclusion: A staging model for late chronic- phase CML can stratify patients in four groups with significantly different outcomes. If confirmed in independent populations, such a model could be considered in the analysis of future trials of treatment strategies in late chronic-phase CML.

Original languageEnglish (US)
Pages (from-to)3782-3787
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number12
DOIs
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Basophils
Survival
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha
Albumins
Referral and Consultation
Splenomegaly
Spleen
Multivariate Analysis
Bone Marrow
Therapeutics
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rodriguez, J., Cortes, J., Smith, T., O'Brien, S., Rios, M. B., Talpaz, M., & Kantarjian, H. (1998). Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology, 16(12), 3782-3787. https://doi.org/10.1200/JCO.1998.16.12.3782

Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. / Rodriguez, Jose; Cortes, Jorge; Smith, Terry; O'Brien, Susan; Rios, Mary Beth; Talpaz, Moshe; Kantarjian, Hagop.

In: Journal of Clinical Oncology, Vol. 16, No. 12, 12.1998, p. 3782-3787.

Research output: Contribution to journalArticle

Rodriguez, J, Cortes, J, Smith, T, O'Brien, S, Rios, MB, Talpaz, M & Kantarjian, H 1998, 'Determinants of prognosis in late chronic-phase chronic myelogenous leukemia', Journal of Clinical Oncology, vol. 16, no. 12, pp. 3782-3787. https://doi.org/10.1200/JCO.1998.16.12.3782
Rodriguez, Jose ; Cortes, Jorge ; Smith, Terry ; O'Brien, Susan ; Rios, Mary Beth ; Talpaz, Moshe ; Kantarjian, Hagop. / Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 12. pp. 3782-3787.
@article{0c49d280686b4b0d9a153138c77323c0,
title = "Determinants of prognosis in late chronic-phase chronic myelogenous leukemia",
abstract = "Purpose: Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic phase (ie, > 12 months after diagnosis). Trials conducted in this phase cannot be evaluated precisely unless the features that determine prognosis in late chronic-phase CML are identified. The purpose of this study is to define the prognostic determinants of late chronic-phase CML. Patients and Methods: From 1980 to 1997, 257 consecutive CML patients referred in late chronic phase were studied. Their clinical characteristics at the time of referral and their association with survival were investigated. A staging model was designed. Results: The median survival from time of referral was 43 months. Pretreatment characteristics associated with worse outcome included older age, poor performance status, splenomegaly; low albumin level, high percentage of blasts or basophils in peripheral blood (PB) or bone marrow, longer duration of chronic phase, and poor-risk group as defined by the Synthesis model. Prior exposure to IFN-A was not associated with worse outcome. By multivariate analysis, characteristics associated with shorter survival were age of 60 years or older, time from diagnosis of 3 years or greater, performance status of 1 or greater, PB basophils of 7{\%} or greater, spleen 10 cm or greater, PB blasts 3{\%} or greater, and albumin level less than 4 g/dL. A model that included age, duration of chronic phase, performance status, and PB basophils was generated. Patients with no, one, two, or three or greater adverse factors had median survivals of 71, 49, 26, and 19 months, respectively. Conclusion: A staging model for late chronic- phase CML can stratify patients in four groups with significantly different outcomes. If confirmed in independent populations, such a model could be considered in the analysis of future trials of treatment strategies in late chronic-phase CML.",
author = "Jose Rodriguez and Jorge Cortes and Terry Smith and Susan O'Brien and Rios, {Mary Beth} and Moshe Talpaz and Hagop Kantarjian",
year = "1998",
month = "12",
doi = "10.1200/JCO.1998.16.12.3782",
language = "English (US)",
volume = "16",
pages = "3782--3787",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

AU - Rodriguez, Jose

AU - Cortes, Jorge

AU - Smith, Terry

AU - O'Brien, Susan

AU - Rios, Mary Beth

AU - Talpaz, Moshe

AU - Kantarjian, Hagop

PY - 1998/12

Y1 - 1998/12

N2 - Purpose: Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic phase (ie, > 12 months after diagnosis). Trials conducted in this phase cannot be evaluated precisely unless the features that determine prognosis in late chronic-phase CML are identified. The purpose of this study is to define the prognostic determinants of late chronic-phase CML. Patients and Methods: From 1980 to 1997, 257 consecutive CML patients referred in late chronic phase were studied. Their clinical characteristics at the time of referral and their association with survival were investigated. A staging model was designed. Results: The median survival from time of referral was 43 months. Pretreatment characteristics associated with worse outcome included older age, poor performance status, splenomegaly; low albumin level, high percentage of blasts or basophils in peripheral blood (PB) or bone marrow, longer duration of chronic phase, and poor-risk group as defined by the Synthesis model. Prior exposure to IFN-A was not associated with worse outcome. By multivariate analysis, characteristics associated with shorter survival were age of 60 years or older, time from diagnosis of 3 years or greater, performance status of 1 or greater, PB basophils of 7% or greater, spleen 10 cm or greater, PB blasts 3% or greater, and albumin level less than 4 g/dL. A model that included age, duration of chronic phase, performance status, and PB basophils was generated. Patients with no, one, two, or three or greater adverse factors had median survivals of 71, 49, 26, and 19 months, respectively. Conclusion: A staging model for late chronic- phase CML can stratify patients in four groups with significantly different outcomes. If confirmed in independent populations, such a model could be considered in the analysis of future trials of treatment strategies in late chronic-phase CML.

AB - Purpose: Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic phase (ie, > 12 months after diagnosis). Trials conducted in this phase cannot be evaluated precisely unless the features that determine prognosis in late chronic-phase CML are identified. The purpose of this study is to define the prognostic determinants of late chronic-phase CML. Patients and Methods: From 1980 to 1997, 257 consecutive CML patients referred in late chronic phase were studied. Their clinical characteristics at the time of referral and their association with survival were investigated. A staging model was designed. Results: The median survival from time of referral was 43 months. Pretreatment characteristics associated with worse outcome included older age, poor performance status, splenomegaly; low albumin level, high percentage of blasts or basophils in peripheral blood (PB) or bone marrow, longer duration of chronic phase, and poor-risk group as defined by the Synthesis model. Prior exposure to IFN-A was not associated with worse outcome. By multivariate analysis, characteristics associated with shorter survival were age of 60 years or older, time from diagnosis of 3 years or greater, performance status of 1 or greater, PB basophils of 7% or greater, spleen 10 cm or greater, PB blasts 3% or greater, and albumin level less than 4 g/dL. A model that included age, duration of chronic phase, performance status, and PB basophils was generated. Patients with no, one, two, or three or greater adverse factors had median survivals of 71, 49, 26, and 19 months, respectively. Conclusion: A staging model for late chronic- phase CML can stratify patients in four groups with significantly different outcomes. If confirmed in independent populations, such a model could be considered in the analysis of future trials of treatment strategies in late chronic-phase CML.

UR - http://www.scopus.com/inward/record.url?scp=0032423158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032423158&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.12.3782

DO - 10.1200/JCO.1998.16.12.3782

M3 - Article

C2 - 9850022

AN - SCOPUS:0032423158

VL - 16

SP - 3782

EP - 3787

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -